Empiric therapy for febrile granulocytopenic patients is mandatory, but whether monotherapy is a safe alternative and whether fluoroquinolones are useful agents for this indication are still controversial issues. The use of monotherapy with intravenous ciprofloxacin (200 to 300 mg every 12 h) was evaluated against combined therapy with piperacillin plus amikacin in febrile granulocytopenic patients with solid tumor or lymphoma. The study was discontinued prematurely because patients treated with ciprofloxacin had a significantly lower overall success rate than patients treated with piperacillin plus amikacin (31 of 48 patients [65%] versus 48 of 53 patients [91%], P = 0.002). Patients with gram-positive coccal bacteremia had a particularly poor outcome: therapy failed for six of eight patients (75%) treated with ciprofloxacin, while therapy failed for none of four patients treated with piperacillin plus amikacin. Death from primary infection during initially randomized protocol therapy occurred in 7 of 48 patients (14.5%) treated with ciprofloxacin and in 3 of 53 (6%) treated with piperacillin plus amikacin. This study does not support the use of this dose of intravenous ciprofloxacin as empiric monotherapy for fever in granulocytopenic patients.
Empiric therapy for febrile granulocytopenic patients is mandatory, but whether monotherapy is a safe alternative and whether fluoroquinolones are useful agents for this indication are still controversial issues. The use of monotherapy with intravenous ciprofloxacin (200 to 300 mg every 12 h) was evaluated against combined therapy with piperacillin plus amikacin in febrile granulocytopenic patients with solid tumor or lymphoma. The study was discontinued prematurely because patients treated with ciprofloxacin had a significantly lower overall success rate than patients treated with piperacillin plus amikacin (31 of 48 patients [65%] versus 48 of 53 patients [91%], P = 0.002). Patients with gram-positive coccal bacteremia had a particularly poor outcome: therapy failed for six of eight patients (75%) treated with ciprofloxacin, while therapy failed for none of four patients treated with piperacillin plus amikacin. Death from primary infection during initially randomized protocol therapy occurred in 7 of 48 patients (14.5%) treated with ciprofloxacin and in 3 of 53 (6%) treated with piperacillin plus amikacin. This study does not support the use of this dose of intravenous ciprofloxacin as empiric monotherapy for fever in granulocytopenic patients.
Optimal empiric therapy in febrile granulocytopenic patients is still controversial and continues to change with new trends in infecting organisms and the availability of new antimicrobial agents. Most often, a combination of a betalactam plus an aminoglycoside is used, since cancer patients who become granulocytopenic are at high risk of developing life threatening infections. Gram-negative bacilli, particularly Pseudomonas aeruginosa, Klebsiella species, and Escherichia coli, along with gram-positive cocci are the predominating infecting organisms (5, 6, 11, 13) . Recently, the incidence of documented bacteremia caused by gramnegative bacilli has declined significantly relative to the increasing incidence of bacteremia caused by gram-positive cocci (13, 17, 20, 21) . A major rationale for empiric therapy with a combination of a beta-lactam plus amikacin has been the provision of rapid and high killing activity in serum, especially for those patients with bacteremia caused by gram-negative bacteria and persistent profound granulocytopenia (<100 granulocytes per ,ul) (6) .
The use of single-antibiotic therapy for febrile, profoundly granulocytopenic cancer patients has been limited by the evidence that the use of two effective agents resulted in synergistic activity and enhanced serum bactericidal effects correlating with a favorable clinical response, especially in gram-negative-rod bacteremia (10) , and because very few antimicrobial compounds had an ideal spectrum for such an approach. The new highly active extended-spectrum cephalosporins offered the opportunity to explore the efficacy of single agents for the empiric treatment of fever in granulocytopenic patients. Recently, successful initial monotherapy with ceftazidime, cefoperazone, or imipenem-cilastatin has been reported (2, 7, 15, 16, 22) .
Ciprofloxacin is a fluoroquinolone antibiotic with bactericidal activity against a broad spectrum of bacteria, including members of the family Enterobacteriaceae, P. aeruginosa, and some gram-positive cocci, including methicillin-susceptible and -resistant Staphylococcus aureus (14) . The safety and pharmacokinetics of intravenous ciprofloxacin administered every 12 h (ql2h) in healthy volunteers as well as in nongranulocytopenic patients have been established (14) . Ciprofloxacin also provides adequate serum bactericidal activity against the bacteria most commonly isolated from cancer patients. This prospective and randomized study evaluates the efficacy, toxicity, and tolerance of monotherapy with intravenous ciprofloxacin compared with those of therapy with piperacillin plus amikacin for empiric therapy in febrile granulocytopenic cancer patients.
(This research was presented as an abstract at the 16th International Congress of Chemotherapy, Jerusalem, Israel, June 1989.) MATERIALS AND METHODS Patient selection. Granulocytopenic cancer patients (over 18 years of age and with an absolute granulocyte count of less than 1,000/4dl) with a chronic hematologic malignancy (excluding patients with acute leukemia and bone marrow transplant recipients), lymphoma, or solid tumor being treated at one of the participating centers of the EORTC International Antimicrobial Therapy Cooperative Group, with a temperature greater than 100.4°F (38°C), were eligible for the study. Patients were excluded if they had received parenteral antibiotics within 4 days before randomization, if they were allergic to any of the trial antibiotics, or if the serum creatinine was greater than 300 pumol/liter. The protocol was approved by the EORTC Protocol Review Committee and by the Human Subjects Committee or Ethics Committee of each participating institution.
Initial and follow-up patient evaluation. Patients were evaluated before randomization and during follow-up as previously published by the Group (5, 6).
Randomization procedure. Patients were randomly allocated, by drawing consecutive sealed envelopes, to one of the following two regimens: ciprofloxacin or piperacillin plus amikacin. The envelopes at each institution were stratified so that equal numbers of patients would be randomized to each trial arm with every six patients entered.
Antibiotic regimens. The dose of piperacillin was 300 mg/kg/day in four divided doses (average dose, 4 to 5 g q6h) plus amikacin at a dose of 15 mg/kg/day in two divided doses (average dose, 500 mg q12h).
The dose of intravenous ciprofloxacin was 6 mg/kg/day in two divided doses (average dose, 200 mg ql2h). However, one center (in the United States) was authorized to use ciprofloxacin at 300 mg ql2h. Study drugs were reconstituted in 50 ml of 5% glucose in water. Piperacillin and amikacin were separately infused intravenously over 15 min, and ciprofloxacin was infused over 30 min.
This study was limited to those patients at relatively low risk of serious infection and excluded those likely to develop persistent profound granulocytopenia and those with acute leukemia. Therefore, most patients had a solid tumor or lymphoma.
Classification of febrile episodes. Episodes of fever were classified as microbiologically documented infection (subclassified into those with or without bacteremia), clinically documented infection, possible infection, or doubtful infection, according to the definitions used by this study group since 1974 (5).
Case review. Each case report was critically reviewed by the data manager and a member of the writing committee before it was included in the data base. In addition, all reports were reviewed by the data review committee, which was blinded to the patient's assigned regimen. This committee was created to ensure uniformity in case reviewing. Its functions include the control of patient eligibility, classification of infection, and the evaluation of response. The data manager and the data review committee were concerned by an apparent high failure rate in one study arm and suggested to the EORTC organizing committee that an interim data analysis be performed. Because of the difference reported herein, the study was discontinued prematurely.
Evaluation of response. Responses to the antibiotic regimens were classified as follows. (i Failure classified because of persistent fever is limited to patients in whom an obvious cause of fever (such as drug fever or fever associated with underlying disease, transfusions, or nonbacterial infection) has been ruled out.
Further infections and death. Superinfection was defined as a new infection, at any site, caused by another organism not recognized as the initial infecting pathogen and occurring either during therapy or within the week after discontinuation of antibiotics. Death was attributed to infection when it occurred as a direct consequence of either the presenting infection or a further infection.
Toxicity. Antibiotic-related hypokalemia was recorded when the serum potassium level fell at least 0.5 meq/liter from the baseline in the absence of a gastrointestinal loss of potassium or treatment with other potassium-depleting drugs. Antibiotic-related nephrotoxicity was defined as a rise in the serum creatinine level of more than 0.5 mg/dl if the baseline was .3 mg/dl or a rise of more than 1 mg/dl if the baseline was >3 mg/dl in the absence of other causes of renal dysfunction (hypotension or hypovolemia) and other nephrotoxic drugs (cisplatin or amphotericin B). Antibiotic-related hepatotoxicity was recorded when the serum aspartate and alanine aminotransferases increased twofold from the baseline in the absence of other causes of hepatic dysfunction and hepatotoxic drugs. Overall, 101 patients were evaluable. The characteristics 5 (10) 4 (8) (21) . Microbiological documentation of infection occurred in 19 patients in the ciprofloxacin group and in 16 patients treated with piperacillin plus amikacin (P = 0.3). Bacteremia occurred in 17 patients treated with ciprofloxacin and in 13 patients who received piperacillin plus amikacin (P = 0.2). Clinically documented infection occurred in 15 and 14 patients, respectively (P = 0.6), and possible infection was recorded for 14 patients treated with ciprofloxacin and 23 patients treated with piperacillin plus amikacin (P = 0.02). As seen in Table 2 , there was a slightly longer duration of therapy in patients assigned to piperacillin and amikacin (P = 0.1), but there was no significant difference in the distribution of the granulocyte counts on the fourth day of therapy or in the number of patients whose granulocyte count ultimately recovered. Evaluation of granulocyte count after day 4 is irrelevant, since a larger number of patients treated with ciprofloxacin were off the study than were those treated with piperacillin plus amikacin (P = 0.01).
The The distribution of bacteremia was as follows: seven patients in each of the treatment arms had bacteremia caused by a single type of gram-negative bacillus (five with E. coli in both groups, two with P. aeruginosa in the ciprofloxacin group), eight patients randomized to the ciprofloxacin arm had bacteremia caused by a single type of gram-positive coccus, compared with four patients treated with piperacillin plus amikacin (P = 0.2). Two patients in both groups had polymicrobial bacteremia. The types of organisms causing infection in the two treatment groups were similar, with slightly more gram-positive-bacterium-caused bacteremia caused by S. aureus (two cases), Streptococcus pneumoniae (two cases), and Enterococcus faecium (two cases) in the ciprofloxacin group. There was no significant difference in the number of treatment failures related to the different ciprofloxacin doses used. Of 37 patients treated with 400 mg of ciprofloxacin daily, treatment of 14 (38%) failed, compared with that for 3 of 11 (27%) treated with 600 mg of ciprofloxacin daily (P = 0.7). Among bacteremias caused by a single type of gram-positive coccus, only two of eight patients responded to ciprofloxacin (all receiving 400 mg of ciprofloxacin), compared with four of four patients treated with piperacillin plus amikacin. However, caution is urged in comparing the two different regimens of ciprofloxacin because of the limited number of patients in this study.
The bacteremic patients were also analyzed according to the antibiotic susceptibility of their isolates. All bacteremic patients successfully treated with ciprofloxacin had susceptible strains, while among the bacteremic patients successfully treated with piperacillin plus amikacin, two had a strain susceptible to amikacin but resistant to piperacillin (one E. coli and one Campylobacter jejuni) and two other patients had a pathogen resistant to amikacin (one Streptococcus mitis and one beta-hemolytic group B streptococcus) but susceptible to piperacillin. The two patients with gramnegative-rod bacteremia whose ciprofloxacin therapy failed were infected with ciprofloxacin-susceptible strains (one E. coli and one P. aeruginosa), and one such patient whose combination therapy failed was infected with an E. coli strain resistant to piperacillin but susceptible to amikacin. Of with E. coli bacteremia, one with Streptococcus pneumoniae bacteremia, one with polymicrobial bacteremia, and one with pneumonia and septic shock but no positive blood cultures. Two patients treated with piperacillin plus amikacin died within 3 days after initiation of empiric therapy: one with E. coli bacteremia and one with polymicrobial bacteremia. The overall mortality was not significantly different in the two groups, nor was the median time to death. Further infections occurred in five patients treated with piperacillin plus amikacin and in one patient treated with ciprofloxacin. All of those infections were documented during therapy with the studied drugs. One patient randomized to receive ciprofloxacin developed positive blood cultures for Streptococcus sanguis and S. mitis (both resistant to ciprofloxacin) 6 days after the initiation of ciprofloxacin.
Two patients treated with piperacillin plus amikacin developed Staphylococcus epidermidis septicemia 3 and 6 days, respectively, after the initiation of empiric therapy. One patient developed a urinary tract infection caused by Candida albicans 3 days after the initiation of piperacillin plus amikacin; one patient had an S. aureus pneumonia documented 10 days after the initiation of piperacillin plus amikacin. Finally, one patient treated for a wound infection caused by Proteus mirabilis developed at the same site on day 5 after the initiation of piperacillin plus amikacin a superinfection caused by Enterobacter aerogenes and C. albicans. Table 4 shows the results for patients with persistent profound granulocytopenia (less than 100 polymorphonu- suggested that 600 mg of ciprofloxacin daily might be more effective in that they reported a higher response rate than the present study. However, the results of this trial do not support the use of low-dose intravenous ciprofloxacin as a single agent for empiric therapy in febrile granulocytopenic patients. The particularly high incidence of documented infections caused by gram-positive cocci in febrile granulocytopenic patients and the poor response rate of those infections treated by ciprofloxacin monotherapy are major arguments for recommending caution when considering empiric therapy with a fluoroquinolone alone.
In addition, fluoroquinolones are frequently recommended for prophylaxis of bacterial infections in neutropenic patients. Various studies have reported the low incidence of gram-negative-bacillus infections documented under these circumstances but a high rate of gram-positive coccal infection (3, 9, 12, 18, 19, 23) . These data suggest that empiric monotherapy with a daily dose of 400 mg of ciprofloxacin should probably not be recommended even for febrile episodes in patients with granulocytopenia of short duration.
